WO2025210569 - HYALURONIC ACID-BASED COMPOSITIONS AND DRY EYE TREATMENT
National phase entry is expected:
Publication Number
WO/2025/210569
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053548
International Filing Date
03.04.2025
Title **
[English]
HYALURONIC ACID-BASED COMPOSITIONS AND DRY EYE TREATMENT
[French]
COMPOSITIONS À BASE D'ACIDE HYALURONIQUE ET TRAITEMENT DE L'OEIL SEC
Applicants **
NORDIC GROUP B.V.
Inventors
PACKER, Mark
HERBAGE, Benjamin
Priority Data
63/574,196
03.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3118 | |
| EPO | Filing, Examination, Granting | 25953 | |
| Japan | Filing, Examination, Granting | 3228 | |
| South Korea | Filing, Examination, Granting | 4130 | |
| USA | Filing, Examination, Granting | 11740 |
Total:
48,169
Contact Us
Abstract[English]
New crosslinked hyaluronic acid gels are provided and use of same as canalicular occlusive devices and to treat dry eye disease. In one aspect, a composition for ocular administration is provided comprising a therapeutically effective amount of 1) crosslinked hyaluronic acid and 2) uncrosslinked hyaluronic acid, wherein the composition has i) a cohesivity value of at least 3 mg according to the drop weight method and ii) a G' elastic modulus of less than 400 Pa.[French]
L'invention concerne de nouveaux gels d'acide hyaluronique réticulé et leur utilisation en tant que dispositifs occlusifs canaliculaires et pour traiter une maladie de l'oeil sec. Selon un aspect, l'invention concerne une composition pour administration oculaire comprenant une quantité thérapeutiquement efficace de 1) de l'acide hyaluronique réticulé et 2) de l'acide hyaluronique non réticulé, la composition ayant i) une valeur de cohésion d'au moins 3 mg selon le procédé stalagmométrique et ii) un module d'élasticité G' inférieur à 400 Pa.